-
Trump says Iran facing 'last chance before decapitation'
-
Trump board reassures Israel after objections on Gaza pullout
-
US northwest battles wildfires after Spokane neighborhoods scorched
-
Zelensky sacks his ambassador to the US
-
Iran denies negotiating with US, drawing Trump backlash
-
'Spider-Man' breaks record for domestic box office debut
-
Key dates for the Boeing 737 MAX
-
US regulators grant long-awaited Boeing 737 MAX 7 certificate
-
Israel objects to US-backed Gaza plan, defiant on pullout
-
Eala powers past Pegula for first WTA title in Washington
-
Norway's Haugset wins stage 3 to claim Tour de France Femmes lead
-
Legionnaires' outbreak in Switzerland's Basel kills one, 26 ill
-
Cuba slowly regains power after latest nationwide blackout
-
Infantino, the FIFA president under pressure after scrapped investor plan
-
Chelsea sign England midfielder Jordan Henderson
-
Young Danes start extended military service
-
Wildfire flares up again in Greece as water bombers deployed
-
England, Wales had driest July on record: Met Office
-
Greece wildfire expert says season 'one of the worst' in a decade
-
French court rejects pro-Kremlin commentator's deportation appeal
-
Sandoz strikes US settlements to resolve generic drug price dispute
-
Oil slides, stocks rise on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan, keeps up strikes on territory
-
EU chief urges 'united action' on borders after Ceuta migrant rush
-
Inside Capital Regency's Market Expansion and User Acquisition
-
Oil prices slide on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan and keeps striking
-
Dortmund sign Greek teenager Karetsas from Genk
-
Bangladesh measles outbreak drives families into debt: aid groups
-
Detained Aung San Suu Kyi meets Red Cross delegate in Myanmar
-
BitMart、説明を迫られる:SNC SCANDIC COINの出金は8日経っても依然としてTXIDなし
-
설명 압박에 직면한 BitMart: 8일이 지나도 여전히 TXID가 없는 SNC SCANDIC COIN 출금
-
Seoul issues first 'severe heatwave warning' under new system
-
BitMart تحت ضغط لتقديم توضيحات: عمليات سحب عملة SNC SCANDIC COIN لا تزال بدون معرّف المعاملة (TXID) بعد مرور ثمانية أيام
-
BitMart змушений надати пояснення: виплати в SNC SCANDIC COIN через вісім днів досі без TXID
-
Welsh FA withdraws support for Infantino's FIFA re-election bid
-
BitMart 面臨解釋壓力:SNC SCANDIC COIN 提現八天後仍無 TXID
-
BitMart under pressure to explain: SNC SCANDIC COIN withdrawals still without a TXID after eight days
-
Cycling superstar Pogacar to ride in Vuelta
-
Iran denies negotiating with US after Trump announces talks
-
Water bombers take to skies as Greece battles wildfires
-
What Europe can learn from Australia's 'Black Summer' wildfires
-
Training the UK 'surgeons of the future' using robots
-
Oil prices sink on Iran hopes, yen gains after joint intervention
-
US, Japan join forces to boost yen
-
Wildfires raze neighborhoods in US northwest city of Spokane
-
Survivors recall blasts before deadly Indonesian ferry fire
-
Trump attorney general pick says has reached deal with senators after standoff
-
Detained Suu Kyi meets Red Cross official in Myanmar: president office
-
Star Australian broadcaster faces trial for sexual assault
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB